LOGIN
Effect of Abaloparatide on Fractures and Bone Density in High-Risk Postmenopausal Women
July 2025
Effect of Abaloparatide on Fractures and Bone Density in High-Risk Postmenopausal Women
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
Effect of abaloparatide on fracture incidence and bone mineral density in postmenopausal women with osteoporosis at highest risk for fracture.
Menopause. 2025 01-May;():. 10.1097/GME.0000000000002516Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Two thousand twenty-six postmenopausal women with osteoporosis at highest fracture risk were randomized to receive either abaloparatide (n=664), teriparatide (n=685), or placebo (n=677) for 18 months. The primary outcome was incidence of new vertebral fractures. Secondary outcomes included incidence of nonvertebral, clinical, major osteoporotic, and wrist fractures, as well as change in bone miner...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.